Skip to main content

Table. 2 Blood hormone levels in study participants with menopausal hormone therapy

From: Effects of menopausal hormone therapy on ambulatory blood pressure and arterial stiffness in postmenopausal Korean women with grade 1 hypertension: a randomized, placebo-controlled trial

 

Placebo (n = 16)

ET (n = 18)

EPT (n = 17)

Baseline 

12 weeks

Change from baseline

Baseline 

12 weeks

Change from baseline

Baseline 

12 weeks

Change from baseline

FSHa

54.6 ± 17.6

53.7 ± 17.2

-0.3 ± 16.9

43.2 ± 14.3

29.5 ± 16.1

-14.5 ± 15.9b

44.1 ± 22.7

24.8 ± 12.1

-20.4 ± 19.4b

E2a

15.5 ± 16.8

42.0 ± 48.0

23.2 ± 56.3

16.4 ± 16.7

119.7 ± 115.4

104.0 ± 112.6b

19.8 ± 32.4

68.3 ± 43.2

56.1 ± 46.6b

P4a

0.2 ± 0.1

0.1 ± 0.1

-0.1 ± 0.1

0.1 ± 0.2

0.1 ± 0.0

-0.1 ± 0.2

0.2 ± 0.3

2.8 ± 2.1

2.5 ± 2.1b

  1. Data are presented as means ± standard deviations
  2. ET estrogen therapy, EPT estrogen + progestogen therapy, FSH follicle stimulating hormone (mIU/mL), E2 estradiol (pg/ml), P4 progesterone (ng/ml)
  3. aP-value for between-group difference at 12 weeks of treatment < 0.05, by the Kruskal Wallis test
  4. bP-value for within-group difference between baseline and 12 weeks of treatment < 0.05, by the signed-rank test
Back to article page

Clinical Hypertension

ISSN: 2056-5909

Contact us